{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,8]],"date-time":"2026-05-08T08:10:48Z","timestamp":1778227848920,"version":"3.51.4"},"reference-count":21,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,4,4]],"date-time":"2026-04-04T00:00:00Z","timestamp":1775260800000},"content-version":"am","delay-in-days":307,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100000060","name":"National Institute of Allergy and Infectious Diseases","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000060","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"NIH","doi-asserted-by":"publisher","award":["UM1AI068636"],"award-info":[{"award-number":["UM1AI068636"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"NIH","doi-asserted-by":"publisher","award":["UM1AI068634"],"award-info":[{"award-number":["UM1AI068634"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"NIH","doi-asserted-by":"publisher","award":["UM1AI106701"],"award-info":[{"award-number":["UM1AI106701"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Contemporary Clinical Trials"],"published-print":{"date-parts":[[2025,6]]},"DOI":"10.1016\/j.cct.2025.107887","type":"journal-article","created":{"date-parts":[[2025,3,26]],"date-time":"2025-03-26T13:47:20Z","timestamp":1742996840000},"page":"107887","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["Implementation of a seamless phase 2\/3 study design in the setting of an emergent infectious disease pandemic: Lessons learned from the ACTIV-2 platform COVID-19 treatment trial"],"prefix":"10.1016","volume":"153","author":[{"given":"Mark J.","family":"Giganti","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kara W.","family":"Chew","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carlee","family":"Moser","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joseph J.","family":"Eron","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mauricio","family":"Pinilla","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jonathan Z.","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Justin","family":"Ritz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Arzhang Cyrus","family":"Javan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David Alain","family":"Wohl","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eric S.","family":"Daar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Judith S.","family":"Currier","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Davey M.","family":"Smith","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael D.","family":"Hughes","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.cct.2025.107887_bb0005","author":"WHO"},{"key":"10.1016\/j.cct.2025.107887_bb0010","doi-asserted-by":"crossref","first-page":"S77","DOI":"10.1093\/infdis\/jiad246","article-title":"ACTIV-2\/A5401 study team, ACTIV-2: a platform trial for the evaluation of novel therapeutics for the treatment of early COVID-19 in outpatients","volume":"228","author":"Currier","year":"2023","journal-title":"J. Infect. Dis."},{"key":"10.1016\/j.cct.2025.107887_bb0015","doi-asserted-by":"crossref","first-page":"S92","DOI":"10.1093\/infdis\/jiad209","article-title":"For the ACTIV-2\/A5401 study team, pooling different placebos as a control Group in a Randomized Platform Trial: benefits and challenges from experience in the ACTIV-2 COVID-19 trial","volume":"228","author":"Moser","year":"2023","journal-title":"J. Infect. Dis."},{"key":"10.1016\/j.cct.2025.107887_bb0020","doi-asserted-by":"crossref","first-page":"658","DOI":"10.7326\/M22-3428","article-title":"Safety and efficacy of combination SARS-CoV-2 neutralizing monoclonal antibodies amubarvimab plus romlusevimab in nonhospitalized patients with COVID-19","volume":"176","author":"Evering","year":"2023","journal-title":"Ann. Intern. Med."},{"key":"10.1016\/j.cct.2025.107887_bb0025","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1177\/0962280210379035","article-title":"Seamless phase II\/III designs","volume":"20","author":"Stallard","year":"2011","journal-title":"Stat. Methods Med. Res."},{"key":"10.1016\/j.cct.2025.107887_bb0030","doi-asserted-by":"crossref","first-page":"1695","DOI":"10.1016\/S0140-6736(20)31042-4","article-title":"Triple combination of interferon beta-1b, lopinavir-ritonavir, and ribavirin in the treatment of patients admitted to hospital with COVID-19: an open-label, randomised, phase 2 trial","volume":"395","author":"Hung","year":"2020","journal-title":"Lancet"},{"key":"10.1016\/j.cct.2025.107887_bb0035","doi-asserted-by":"crossref","first-page":"e440","DOI":"10.1093\/cid\/ciab912","article-title":"Placebo-controlled clinical trial of Bamlanivimab and Etesevimab together in high-risk ambulatory patients with COVID-19 and validation of the prognostic value of persistently high viral load","volume":"75","author":"Dougan","year":"2022","journal-title":"Clin. Infect. Dis."},{"key":"10.1016\/j.cct.2025.107887_bb0040","article-title":"REGEN-COV antibody combination and outcomes in outpatients with covid-19","author":"Weinreich","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.cct.2025.107887_bb0045","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1177\/2168479014533970","article-title":"Bayesian design of proof-of-concept trials","volume":"49","author":"Fisch","year":"2015","journal-title":"Ther. Innov. Regul. Sci."},{"key":"10.1016\/j.cct.2025.107887_bb0050","doi-asserted-by":"crossref","first-page":"549","DOI":"10.2307\/2530245","article-title":"A multiple testing procedure for clinical trials","volume":"35","author":"O\u2019Brien","year":"1979","journal-title":"Biometrics"},{"key":"10.1016\/j.cct.2025.107887_bb0055","doi-asserted-by":"crossref","first-page":"1439","DOI":"10.1002\/sim.4780091207","article-title":"Group sequential designs using a family of type I error probability spending functions","volume":"9","author":"Hwang","year":"1990","journal-title":"Stat. Med."},{"key":"10.1016\/j.cct.2025.107887_bb0060","doi-asserted-by":"crossref","first-page":"4931","DOI":"10.1038\/s41467-022-32551-2","article-title":"Antiviral and clinical activity of bamlanivimab in a randomized trial of non-hospitalized adults with COVID-19","volume":"13","author":"Chew","year":"2022","journal-title":"Nat. Commun."},{"key":"10.1016\/j.cct.2025.107887_bb0065","doi-asserted-by":"crossref","first-page":"S117","DOI":"10.1093\/infdis\/jiad287","article-title":"ACTIV-2\/A5401 study team, association between anterior nasal and plasma SARS-CoV-2 RNA levels and hospitalization or death in nonhospitalized adults with mild-to-moderate COVID-19","volume":"228","author":"Giganti","year":"2023","journal-title":"J. Infect. Dis."},{"key":"10.1016\/j.cct.2025.107887_bb0070","doi-asserted-by":"crossref","first-page":"941","DOI":"10.1093\/cid\/ciad342","article-title":"One week of oral camostat versus placebo in nonhospitalized adults with mild-to-moderate coronavirus disease 2019: a randomized controlled phase 2 trial","volume":"77","author":"Jilg","year":"2023","journal-title":"Clin. Infect. Dis."},{"key":"10.1016\/j.cct.2025.107887_bb0075","first-page":"175","article-title":"A randomized controlled trial of camostat in outpatients with COVID-19 [CROI abstract 459]","volume":"30","author":"Jilg","year":"2022","journal-title":"Topics Antiviral Med."},{"key":"10.1016\/j.cct.2025.107887_bb0080","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1093\/infdis\/jiad013","article-title":"ACTIV-2\/A5401 study team, phase 2 safety and antiviral activity of SAB-185, a novel polyclonal antibody therapy for nonhospitalized adults with COVID-19","volume":"228","author":"Taiwo","year":"2023","journal-title":"J. Infect. Dis."},{"key":"10.1016\/j.cct.2025.107887_bb0085","doi-asserted-by":"crossref","DOI":"10.1093\/infdis\/jiae369","article-title":"Safety and efficacy of SAB-185 for non-hospitalized adults with COVID-19: a randomized clinical trial","author":"Chew","year":"2024","journal-title":"J. Infect. Dis."},{"key":"10.1016\/j.cct.2025.107887_bb0090","doi-asserted-by":"crossref","DOI":"10.1016\/j.eclinm.2023.102250","article-title":"ACTIV-2\/A5401 study team, safety and efficacy of inhaled interferon-\u03b21a (SNG001) in adults with mild-to-moderate COVID-19: a randomized, controlled, phase II trial","volume":"65","author":"Jagannathan","year":"2023","journal-title":"EClinicalMedicine"},{"key":"10.1016\/j.cct.2025.107887_bb0095","first-page":"138","volume":"9","author":"Corado","year":"2024","journal-title":"Pathog. Immun."},{"key":"10.1016\/j.cct.2025.107887_bb0100","article-title":"Viral clearance as a surrogate of clinical efficacy for COVID-19 therapies in outpatients: A systematic review and meta-analysis","author":"Elias","year":"2023","journal-title":"Lancet"},{"key":"10.1016\/j.cct.2025.107887_bb0105","doi-asserted-by":"crossref","first-page":"2038","DOI":"10.1093\/jac\/dkac104","article-title":"Clinical relevance of nasopharyngeal SARS-CoV-2 viral load reduction in outpatients with COVID-19","volume":"77","author":"Parienti","year":"2022","journal-title":"J. Antimicrob. Chemother."}],"container-title":["Contemporary Clinical Trials"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1551714425000813?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1551714425000813?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,8]],"date-time":"2026-05-08T07:19:56Z","timestamp":1778224796000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1551714425000813"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6]]},"references-count":21,"alternative-id":["S1551714425000813"],"URL":"https:\/\/doi.org\/10.1016\/j.cct.2025.107887","relation":{},"ISSN":["1551-7144"],"issn-type":[{"value":"1551-7144","type":"print"}],"subject":[],"published":{"date-parts":[[2025,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Implementation of a seamless phase 2\/3 study design in the setting of an emergent infectious disease pandemic: Lessons learned from the ACTIV-2 platform COVID-19 treatment trial","name":"articletitle","label":"Article Title"},{"value":"Contemporary Clinical Trials","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.cct.2025.107887","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"107887"}}